Pharmacology Corner

Articles related to ‘EMEA media releases’

• EMEA recommends new contraindication for aliskiren (Rasilez): angioedema

  2/21/09 • (1)

• Efalizumab (Raptiva) for plaque psoriasis. EMEA recommends withdrawal of its marketing authorization, FDA issues public health advisory

  2/19/09 • (0)

• Vorinostat MSD for cutaneous T-cell lymphoma. MSD withdraws marketing application

  2/17/09 • (0)

• EMEA recommends new contraindications for toremifene (Fareston): long QT interval and related heart diseases

  1/24/09 • (0)

• EMEA public statement on the market withdrawal of Daclizumab (Zenapax)

  1/24/09 • (0)

• Ramipril (Tritrace): indications, contraindications and posology updated in a review by the CHMP

  1/07/09 • (0)

• EMEA: marketing authorisation of Nespo (darbepoetin alfa) withdrawed

  12/22/08 • (0)

• EMEA: marketing authorisation of Neupopeg (pegfilgrastim) withdrawed

  12/22/08 • (0)

• EMEA press release: CHMP adopted positive opinion about mifamurtide (Mepact) for the treatment of osteosarcoma

  12/20/08 • (0)

• EMEA press release: CHMP positive opinion about degarelix (Firmagon) for prostate cancer

  12/19/08 • (0)

• CHMP positive opinion for lasofoxifene (Fablyn), a new SERM

  12/18/08 • (0)

• CHMP positive opinion for new indication of miglustat (Zavesca)

  12/18/08 • (0)

• EMEA positive opinion for prasugrel (Efient)

  12/18/08 • (0)

• EMEA press release: CHMP adopted a positive opinion about japanese encephalitis vaccine (Ixiaro)

  12/18/08 • (0)

© 2010 • Continuing medical education in clinical Pharmacology and Therapeutics | Pharmamotion | Powered by WordPress & Mimbo

Blog Entries • Comments